DB:TQB2

Stock Analysis Report

Executive Summary

ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, and Europe.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.

Risks

  • ImmunoPrecise Antibodies is covered by less than 3 analysts.

Share Price & News

How has ImmunoPrecise Antibodies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.2%

DB:TQB2

3.4%

DE Life Sciences

3.2%

DE Market


1 Year Return

-35.6%

DB:TQB2

5.2%

DE Life Sciences

-9.7%

DE Market

TQB2 underperformed the Life Sciences industry which returned 7.1% over the past year.

TQB2 underperformed the Market in Germany which returned -9.6% over the past year.


Share holder returns

TQB2IndustryMarket
7 Day8.2%3.4%3.2%
30 Day6.2%-3.8%-4.4%
90 Day-0.8%3.9%-2.0%
1 Year-35.6%-35.6%6.1%5.2%-6.9%-9.7%
3 Yearn/a76.2%67.1%11.8%2.2%
5 Yearn/a225.6%201.1%26.9%9.5%

Price Volatility Vs. Market

How volatile is ImmunoPrecise Antibodies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ImmunoPrecise Antibodies undervalued based on future cash flows and its price relative to the stock market?

2.2x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for ImmunoPrecise Antibodies to establish if it is available at moderate discount.

Unable to calculate intrinsic value for ImmunoPrecise Antibodies to establish if it is available at substantial discount.


Price Based on Earnings

ImmunoPrecise Antibodies is loss making, we can't compare its value to the Europe Life Sciences industry average.

ImmunoPrecise Antibodies is loss making, we can't compare the value of its earnings to the Germany market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ImmunoPrecise Antibodies, we can't assess if its growth is good value.


Price Based on Value of Assets

ImmunoPrecise Antibodies is good value based on assets compared to the Europe Life Sciences industry average.


Next Steps

Future Growth

How is ImmunoPrecise Antibodies expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

29.3%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

ImmunoPrecise Antibodies's revenue is expected to grow significantly at over 20% yearly.

Unable to determine if ImmunoPrecise Antibodies is high growth as no earnings estimate data is available.

ImmunoPrecise Antibodies's revenue growth is expected to exceed the Germany market average.

Unable to compare ImmunoPrecise Antibodies's earnings growth to the Germany market average as no estimate data is available.

Unable to compare ImmunoPrecise Antibodies's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if ImmunoPrecise Antibodies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has ImmunoPrecise Antibodies performed over the past 5 years?

-55.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ImmunoPrecise Antibodies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare ImmunoPrecise Antibodies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ImmunoPrecise Antibodies's 1-year growth to the Europe Life Sciences industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ImmunoPrecise Antibodies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ImmunoPrecise Antibodies has efficiently used its assets last year compared to the Europe Life Sciences industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ImmunoPrecise Antibodies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ImmunoPrecise Antibodies's financial position?


Financial Position Analysis

ImmunoPrecise Antibodies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ImmunoPrecise Antibodies's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

ImmunoPrecise Antibodies's level of debt (13.8%) compared to net worth is satisfactory (less than 40%).

Unable to establish if ImmunoPrecise Antibodies's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3.5x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ImmunoPrecise Antibodies has sufficient cash runway for 1.9 years based on current free cash flow.

ImmunoPrecise Antibodies has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 80% each year.


Next Steps

Dividend

What is ImmunoPrecise Antibodies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ImmunoPrecise Antibodies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ImmunoPrecise Antibodies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ImmunoPrecise Antibodies has not reported any payouts.

Unable to verify if ImmunoPrecise Antibodies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ImmunoPrecise Antibodies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of ImmunoPrecise Antibodies's salary, the management and board of directors tenure and is there insider trading?

1.6yrs

Average management tenure


CEO

Jennifer Bath 0

1.5yrs

Tenure

CA$64,583

Compensation

Dr. Jennifer Bath has been the Chief Executive Officer and President of ImmunoPrecise Antibodies Ltd. since February 21, 2018. Dr. Bath served as the Global Director of Client Relations at Aldevron, LLC, w ...


CEO Compensation Analysis

Jennifer's remuneration is lower than average for companies of similar size in Germany.

Insufficient data for Jennifer to compare compensation growth.


Management Age and Tenure

1.6yrs

Average Tenure

The average tenure for the ImmunoPrecise Antibodies management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.6yrs

Average Tenure

54.5yo

Average Age

The average tenure for the ImmunoPrecise Antibodies board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by ImmunoPrecise Antibodies individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyCA$2,22817 Jul 19
Jennifer Bath
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceCA$0.45
BuyCA$4,58931 May 19
Paul Andreola
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceCA$0.46
SellCA$15,94101 Mar 19
Immusys B.V.
EntityCompany
Shares32,074
Max PriceCA$0.50
BuyCA$4,00122 Feb 19
Jennifer Bath
EntityIndividual
Role
Chief Executive Officer
President
Shares8,100
Max PriceCA$0.49
BuyCA$2,03615 Feb 19
Paul Andreola
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceCA$0.41
BuyCA$1,60701 Feb 19
Paul Andreola
EntityIndividual
Role
Member of the Board of Directors
Director
Shares3,500
Max PriceCA$0.46
BuyCA$8,57510 Dec 18
Paul Andreola
EntityIndividual
Role
Member of the Board of Directors
Director
Shares20,000
Max PriceCA$0.43
SellCA$115,41511 Oct 18
Immusys B.V.
EntityCompany
Shares200,000
Max PriceCA$0.62
SellCA$5,91605 Oct 18
Martin Hessing
EntityIndividual
Shares10,000
Max PriceCA$0.62
BuyCA$164,08228 Sep 18
Topanga Oü
EntityCompany
Shares250,000
Max PriceCA$0.66
BuyCA$164,08228 Sep 18
Kokkuhoideur OU
EntityCompany
Shares250,000
Max PriceCA$0.66
BuyCA$656,32728 Sep 18
Serenga Ou
EntityCompany
Shares1,000,000
Max PriceCA$0.66
SellCA$57,39230 Aug 18
Immusys B.V.
EntityCompany
Shares88,000
Max PriceCA$0.65

Ownership Breakdown


Management Team

  • Jim Kuo (54yo)

    Chairman

    • Tenure: 0.0yrs
  • David Orton

    Chief Operating Officer

    • Tenure: 2.4yrs
  • Lisa Helbling

    Chief Financial Officer

    • Tenure: 0.6yrs
  • Robert Beecroft

    Founder & Director

    • Tenure: 24.3yrs
    • Compensation: CA$151.05k
  • Lauren Smith

    Vice President of Marketing and Sales

    • Tenure: 2.3yrs
  • Jennifer Bath

    President

    • Tenure: 1.5yrs
    • Compensation: CA$64.58k
  • Chip Wheelock

    Global Chief Technology Officer

    • Tenure: 1.3yrs
    • Compensation: CA$11.15k

Board Members

  • Jim Kuo (54yo)

    Chairman

    • Tenure: 0.0yrs
  • Paul Andreola (55yo)

    Director

    • Tenure: 1.6yrs
  • Greg Smith (52yo)

    Director

    • Tenure: 3.1yrs
  • Guy Champagne (63yo)

    Member of Advisory Board

    • Tenure: 1.0yrs
    • Compensation: CA$55.00k
  • Robert Beecroft

    Founder & Director

    • Tenure: 24.3yrs
    • Compensation: CA$151.05k
  • Jennifer Bath

    President

    • Tenure: 1.5yrs
    • Compensation: CA$64.58k
  • Robert Burke

    Director

    • Tenure: 1.7yrs

Company Information

ImmunoPrecise Antibodies Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ImmunoPrecise Antibodies Ltd.
  • Ticker: TQB2
  • Exchange: DB
  • Founded: 1989
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$44.193m
  • Listing Market Cap: CA$30.005m
  • Shares outstanding: 67.99m
  • Website: https://www.immunoprecise.com

Location

  • ImmunoPrecise Antibodies Ltd.
  • Vancouver Island Technology Park
  • Unit 3204
  • Victoria
  • British Columbia
  • V8Z 7X8
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPATSXV (TSX Venture Exchange)YesCommon SharesCACADDec 2016
IPAT.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDDec 2016
TQB2DB (Deutsche Boerse AG)YesCommon SharesDEEURDec 2016

Biography

ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, and Europe. It also provides human antibody development, hybridoma development, genetic i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 22:14
End of Day Share Price2019/08/22 00:00
Earnings2019/01/31
Annual Earnings2018/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.